28 related articles for article (PubMed ID: 21357681)
1. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.
Bielefeldt-Ohmann H; Marzo AL; Himbeck RP; Jarnicki AG; Robinson BW; Fitzpatrick DR
Cancer Immunol Immunother; 1995 Apr; 40(4):241-50. PubMed ID: 7750122
[TBL] [Abstract][Full Text] [Related]
2. The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance.
Strober W; Kitani A; Fichtner-Feigl S; Fuss IJ
Curr Mol Med; 2009 Aug; 9(6):740-50. PubMed ID: 19689301
[TBL] [Abstract][Full Text] [Related]
3. Combination strategies to enhance antitumor ADCC.
Kohrt HE; Houot R; Marabelle A; Cho HJ; Osman K; Goldstein M; Levy R; Brody J
Immunotherapy; 2012 May; 4(5):511-27. PubMed ID: 22642334
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
5. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Coral S; Sigalotti L; Colizzi F; Spessotto A; Nardi G; Cortini E; Pezzani L; Fratta E; Fonsatti E; Di Giacomo AM; Nicotra MR; Natali PG; Altomonte M; Maio M
J Cell Physiol; 2006 Apr; 207(1):58-66. PubMed ID: 16252259
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
[TBL] [Abstract][Full Text] [Related]
10. IL-13 receptor-directed cancer vaccines and immunotherapy.
Nakashima H; Husain SR; Puri RK
Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
[TBL] [Abstract][Full Text] [Related]
11. Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.
Kawakami K
Curr Gene Ther; 2005 Apr; 5(2):213-23. PubMed ID: 15853729
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.
Knudson KM; Hwang S; McCann MS; Joshi BH; Husain SR; Puri RK
Front Immunol; 2022; 13():878365. PubMed ID: 35464460
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]